EA201791617A1 - Аналоги амилина - Google Patents

Аналоги амилина

Info

Publication number
EA201791617A1
EA201791617A1 EA201791617A EA201791617A EA201791617A1 EA 201791617 A1 EA201791617 A1 EA 201791617A1 EA 201791617 A EA201791617 A EA 201791617A EA 201791617 A EA201791617 A EA 201791617A EA 201791617 A1 EA201791617 A1 EA 201791617A1
Authority
EA
Eurasian Patent Office
Prior art keywords
analogues
amilina
analogs
diseases
diabetes
Prior art date
Application number
EA201791617A
Other languages
English (en)
Other versions
EA035791B1 (ru
Inventor
Расмус Юст
Оливер Деммер
Лисе Гим
Йеспер Слот Вилладсен
Хенрик Кофод Мунк
Йоланта Скарбалиене
Мария Александровна Дерябина
Дитер Вольфганг Хампрехт
Йеспер Мосольфф Матисен
Original Assignee
Зилэнд Фарма А/С
Бёрингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52779493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201791617(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Зилэнд Фарма А/С, Бёрингер Ингельхайм Интернациональ Гмбх filed Critical Зилэнд Фарма А/С
Publication of EA201791617A1 publication Critical patent/EA201791617A1/ru
Publication of EA035791B1 publication Critical patent/EA035791B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)

Abstract

Настоящее изобретение относится к аналогам амилина и к применению указанных аналогов в лечении или предотвращении множества заболеваний, состояний или нарушений, включая ожирение, избыточное потребление пищи и связанные метаболические заболевания, такие как диабет. Указанные аналоги обладают высокой физической и химической стабильностью, хорошей растворимостью и большой длительностью действия и хорошо подходят для применения в форме жидкого препарата.
EA201791617A 2015-03-18 2016-03-17 Аналоги амилина EA035791B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15159737 2015-03-18
PCT/EP2016/055793 WO2016146739A1 (en) 2015-03-18 2016-03-17 Amylin analogues

Publications (2)

Publication Number Publication Date
EA201791617A1 true EA201791617A1 (ru) 2018-02-28
EA035791B1 EA035791B1 (ru) 2020-08-11

Family

ID=52779493

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791617A EA035791B1 (ru) 2015-03-18 2016-03-17 Аналоги амилина

Country Status (19)

Country Link
US (2) US10766939B2 (ru)
EP (1) EP3271381B1 (ru)
JP (1) JP6769984B2 (ru)
KR (1) KR20170126504A (ru)
CN (1) CN107567459B (ru)
AR (1) AR103954A1 (ru)
AU (1) AU2016232218B2 (ru)
BR (1) BR112017019378A2 (ru)
CA (1) CA2979950A1 (ru)
CL (1) CL2017002256A1 (ru)
CO (1) CO2017008870A2 (ru)
EA (1) EA035791B1 (ru)
IL (1) IL253924A0 (ru)
MX (1) MX2017011182A (ru)
PE (1) PE20180497A1 (ru)
PH (1) PH12017501674A1 (ru)
SG (1) SG11201707286UA (ru)
TW (1) TW201706294A (ru)
WO (1) WO2016146739A1 (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017011182A (es) 2015-03-18 2018-06-06 Zealand Pharma As Analogos de amilina.
US10071140B2 (en) 2016-09-09 2018-09-11 Zealand Pharma A/S Amylin analogues
JP2022504596A (ja) 2018-10-11 2022-01-13 インターシア セラピューティクス，インコーポレイティド ヒトアミリンアナログペプチド及び使用方法
CR20220206A (es) 2019-11-11 2022-06-16 Boehringer Ingelheim Int Agonistas del receptor npy2
AU2021260870A1 (en) * 2020-04-20 2022-12-08 I2O Therapeutics, Inc. Use of human amylin analog polypeptides for providing superior glycemic control to type 1 diabetics
BR112022025623A2 (pt) 2020-08-07 2023-03-07 Boehringer Ingelheim Int Agonistas solúveis de receptores de npy2
DK4021929T5 (da) 2020-09-24 2023-07-17 Gubra As hAM15-52-analoger med forbedret amylinreceptor (hAMY3R)-potens
EP4144362A1 (en) 2021-09-06 2023-03-08 Adocia Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition
WO2022248419A2 (en) 2021-05-22 2022-12-01 Adocia Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition
EP4129324A1 (en) 2021-08-02 2023-02-08 Adocia Compositions comprising at least an amylin receptor agonist and a glp-1 receptor agonist
CN113893349B (zh) * 2021-12-13 2022-07-22 北京大学第三医院（北京大学第三临床医学院） 达格列净及其类似物在制备防治雄性生殖功能障碍的药物中的用途
WO2023227133A1 (zh) * 2022-05-27 2023-11-30 杭州先为达生物科技股份有限公司 人胰淀素类似物、其衍生物及用途
EP4319798A1 (en) * 2022-05-30 2024-02-14 Zealand Pharma A/S Liquid formulations of amylin analogues
WO2024022465A1 (zh) * 2022-07-29 2024-02-01 杭州九源基因工程有限公司 一种人胰淀素多肽衍生物及其用途

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175146A (en) 1989-12-05 1992-12-29 Vical, Inc. Synthetic calcitonin peptides
US5234906A (en) 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
CA2100745C (en) 1991-11-19 2007-07-31 Laura S. L. Gaeta Amylin agonist peptides and uses therefor
KR100429966B1 (ko) 1993-09-07 2004-05-04 아밀린 파마슈티칼스, 인크. 위장 운동성 조절을 위한 제약 조성물
CA2468374C (en) 1996-08-30 2010-12-21 Novo-Nordisk A/S Glp-1 derivatives
CZ295838B6 (cs) 1996-09-09 2005-11-16 Zealand Pharma A/S Způsob výroby peptidů
US5677279A (en) 1996-12-16 1997-10-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treating pain with amylin or agonists thereof
US7101853B2 (en) 1997-05-06 2006-09-05 Amylin Pharmaceuticals, Inc. Method for treating or preventing gastritis using amylin or amylin agonists
US7910548B2 (en) 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
WO1999034764A2 (en) 1998-01-09 1999-07-15 Amylin Pharmaceuticals, Inc. Amylin agonist pharmaceutical compositions containing insulin
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
BR0009040A (pt) 1999-03-17 2001-12-18 Novo Nordisk As Método para acilar um grupo amino de um peptìdeoou de uma proteìna, e, composto
US8008255B2 (en) 2003-05-30 2011-08-30 Amylin Pharmaceuticals, Inc. Methods and compositions for enhanced transmucosal delivery of peptides and proteins
BRPI0507623A (pt) 2004-02-11 2007-07-03 Amylin Pharmaceuticals Inc peptìdeos da famìlia da amilina e métodos para prepará-los e empregá-los
NZ548978A (en) 2004-02-11 2009-10-30 Amylin Pharmaceuticals Inc Hybrid polypeptides with selectable properties
DE102004051014A1 (de) 2004-10-20 2006-04-27 Rwth Aachen Chemisch modifizierte Peptidanaloga
US20090286723A1 (en) 2005-02-11 2009-11-19 Amylin Pharmaceuticals, Inc. Hybrid Polypeptides with Selectable Properties
WO2007104789A2 (en) 2006-03-15 2007-09-20 Novo Nordisk A/S Amylin derivatives
BRPI0807728A2 (pt) 2007-02-15 2012-04-17 Univ Indiana Res & Tech Corp co-agonistas de receptor glucagon/glp-1
WO2008152403A1 (en) 2007-06-15 2008-12-18 Zealand Pharma A/S Glucagon analogues
EP2036923A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Improved derivates of amylin
EP2036539A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Stable formulations of amylin and its analogues
EP2340261B1 (en) 2008-10-21 2017-12-20 Novo Nordisk A/S Amylin derivatives
MX2011006313A (es) 2008-12-15 2011-09-27 Zealand Pharma As Analogos de glucagon.
BRPI0823377A2 (pt) 2008-12-15 2016-09-27 Zealand Pharma As análogos de glucagon
BRPI0823379A2 (pt) 2008-12-15 2015-07-14 Zealand Pharma As Análogos de glucagon
DK2370460T3 (da) 2008-12-15 2014-08-04 Zealand Pharma As Glucagon analoger
WO2010107874A2 (en) 2009-03-17 2010-09-23 Amylin Pharmaceuticals, Inc. Methods for affecting body composition using amylin agonists
DK2454282T3 (en) 2009-07-13 2015-05-04 Zealand Pharma As acetylated glucagonanaloger
US8815541B2 (en) 2009-11-25 2014-08-26 Novo Nordisk A/S Method for making polypeptides
AR081975A1 (es) 2010-06-23 2012-10-31 Zealand Pharma As Analogos de glucagon
EP2585482B1 (en) 2010-06-24 2019-03-27 Zealand Pharma A/S Glucagon analogues
US8722849B2 (en) 2011-06-10 2014-05-13 Novo Nordisk A/S Polypeptides
CN104144696A (zh) 2011-12-23 2014-11-12 西兰制药公司 胰高血糖素类似物
PL2838914T3 (pl) * 2012-04-19 2017-11-30 Novo Nordisk A/S Analogi ludzkiej amyliny
US8575091B1 (en) 2012-04-19 2013-11-05 Novo Nordisk A/S Amylin analogues and pharmaceutical compositions thereof
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
AR097701A1 (es) * 2013-09-19 2016-04-13 Zealand Pharma As Análogos de amilina
JP2016208556A (ja) * 2013-10-03 2016-12-08 三菱電機株式会社 デマンド予測装置及びデマンド予測方法
DK3137494T3 (da) 2014-05-02 2021-10-04 Univ New York State Res Found Isletamyloidpolypeptider med forbedret opløselighed
AR101742A1 (es) 2014-09-04 2017-01-11 Novo Nordisk As Agonista del receptor de calcitonina y amilina
MX2017011182A (es) 2015-03-18 2018-06-06 Zealand Pharma As Analogos de amilina.
US10071140B2 (en) 2016-09-09 2018-09-11 Zealand Pharma A/S Amylin analogues

Also Published As

Publication number Publication date
BR112017019378A2 (pt) 2019-02-19
AU2016232218B2 (en) 2020-09-10
CA2979950A1 (en) 2016-09-22
PH12017501674A1 (en) 2018-03-12
MX2017011182A (es) 2018-06-06
AR103954A1 (es) 2017-06-14
US20160272693A1 (en) 2016-09-22
PE20180497A1 (es) 2018-03-09
JP2018510871A (ja) 2018-04-19
EP3271381A1 (en) 2018-01-24
EP3271381B1 (en) 2021-09-08
US20210115104A1 (en) 2021-04-22
SG11201707286UA (en) 2017-10-30
US10766939B2 (en) 2020-09-08
CO2017008870A2 (es) 2017-11-10
CN107567459A (zh) 2018-01-09
KR20170126504A (ko) 2017-11-17
EA035791B1 (ru) 2020-08-11
CL2017002256A1 (es) 2018-04-02
IL253924A0 (en) 2017-10-31
AU2016232218A1 (en) 2017-09-21
JP6769984B2 (ja) 2020-10-14
TW201706294A (zh) 2017-02-16
CN107567459B (zh) 2021-09-24
WO2016146739A1 (en) 2016-09-22

Similar Documents

Publication Publication Date Title
EA201791617A1 (ru) Аналоги амилина
EA201990360A1 (ru) Аналоги амилина
EA201792354A1 (ru) Композиции обетихолевой кислоты и способы применения
EA201800367A1 (ru) Способы лечения болезни хантингтона
EA201692177A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
EA201890767A1 (ru) C4-модифицированные производные олеаноловой кислоты для ингибирования il-17 и других применений
EA201590058A1 (ru) Аналоги глюкагона
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201591839A1 (ru) Терапевтические пептиды
EA201590011A1 (ru) Пептидные аналоги эксендина-4
MX2016013243A (es) Agonistas peptídicos duales de los receptores de glp-1/glucagón derivados de la exendina-4.
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
EA201692007A1 (ru) Соединения изоиндолинона в качестве модуляторов gpr119 для лечения диабета, ожирения, дислипидемии и связанных с ними нарушений
MX2021010060A (es) Produccion de virus en huevos aviares.
EA201692049A1 (ru) Гетероарилзамещенные гетероциклилсульфоны
EA201890449A1 (ru) Фумагиллиновые гетероциклические соединения и способы их получения и применения
EA201891727A1 (ru) Композиции на основе дейтерированного домперидона и способы терапии расстройств
EA202091020A1 (ru) Замещенные имидазопиридинамиды и их применение
EA201790912A1 (ru) Гетероциклическое соединение
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
EA201791432A1 (ru) Композиции на основе пролекарства монометилфумарата
EA201791611A1 (ru) Лечение пациентов детского возраста с сахарным диабетом 2 типа с помощью ликсисенатида
EA201691792A1 (ru) Фармацевтические составы на основе вилдаглиптина
EA201691498A1 (ru) Новая мишень для лечения и профилактики диабета
EA201791154A1 (ru) Лечение болезней и нарушений аналогами кальцитонина